MX2020003730A - Nueva sal y formas en estado solido de escitalopram. - Google Patents
Nueva sal y formas en estado solido de escitalopram.Info
- Publication number
- MX2020003730A MX2020003730A MX2020003730A MX2020003730A MX2020003730A MX 2020003730 A MX2020003730 A MX 2020003730A MX 2020003730 A MX2020003730 A MX 2020003730A MX 2020003730 A MX2020003730 A MX 2020003730A MX 2020003730 A MX2020003730 A MX 2020003730A
- Authority
- MX
- Mexico
- Prior art keywords
- solid state
- escitalopram
- state forms
- new salt
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción se refiere a una nueva sal de escitalopram y sus formas en estado sólido, procesos para la preparación de la misma, sus composiciones farmacéuticas y sus métodos de uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762569755P | 2017-10-09 | 2017-10-09 | |
| PCT/IB2018/057824 WO2019073388A1 (en) | 2017-10-09 | 2018-10-09 | NEW SALT AND FORMS IN THE STRONG STATE OF ESCITALOPRAM |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003730A true MX2020003730A (es) | 2020-08-03 |
Family
ID=64100686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003730A MX2020003730A (es) | 2017-10-09 | 2018-10-09 | Nueva sal y formas en estado solido de escitalopram. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11390597B2 (es) |
| EP (1) | EP3694843B1 (es) |
| JP (1) | JP7237269B2 (es) |
| KR (1) | KR102505669B1 (es) |
| CN (1) | CN111194312A (es) |
| AU (1) | AU2018349284B2 (es) |
| CA (2) | CA3215809A1 (es) |
| ES (1) | ES2911894T3 (es) |
| MX (1) | MX2020003730A (es) |
| PL (1) | PL3694843T3 (es) |
| RU (1) | RU2020111694A (es) |
| WO (1) | WO2019073388A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11390597B2 (en) * | 2017-10-09 | 2022-07-19 | Mark Hasleton | Salt and solid state forms of escitalopram |
| US20240100012A1 (en) * | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
| AU2022308198A1 (en) * | 2021-07-06 | 2024-02-01 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8814057D0 (en) | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| RS51092B (sr) * | 2002-12-23 | 2010-10-31 | H. Lundbeck A/S. | Escitalopram bromhidrat i postupak za njegovo pripremanje |
| US20050154052A1 (en) * | 2003-03-24 | 2005-07-14 | Hetero Drugs Limited | Novel crystalline forms of (s)-citalopram oxalate |
| KR100841409B1 (ko) * | 2003-12-16 | 2008-06-25 | 에스케이케미칼주식회사 | 암로디핀 겐티세이트 염과 이의 제조방법 |
| US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| KR101235116B1 (ko) * | 2005-10-17 | 2013-02-20 | 에스케이케미칼주식회사 | 광학활성 암로디핀 겐티세이트 염의 제조방법 |
| EP2231648A1 (en) * | 2007-12-05 | 2010-09-29 | BIAL - Portela & Ca., S.A. | New salts and crystal forms |
| TW201729810A (zh) * | 2015-10-26 | 2017-09-01 | 札爾科製藥公司 | 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法 |
| US11390597B2 (en) * | 2017-10-09 | 2022-07-19 | Mark Hasleton | Salt and solid state forms of escitalopram |
-
2018
- 2018-10-09 US US16/764,033 patent/US11390597B2/en active Active
- 2018-10-09 AU AU2018349284A patent/AU2018349284B2/en active Active
- 2018-10-09 CN CN201880065569.2A patent/CN111194312A/zh active Pending
- 2018-10-09 CA CA3215809A patent/CA3215809A1/en active Pending
- 2018-10-09 KR KR1020207010847A patent/KR102505669B1/ko active IP Right Grant
- 2018-10-09 WO PCT/IB2018/057824 patent/WO2019073388A1/en unknown
- 2018-10-09 MX MX2020003730A patent/MX2020003730A/es unknown
- 2018-10-09 EP EP18796753.4A patent/EP3694843B1/en active Active
- 2018-10-09 PL PL18796753T patent/PL3694843T3/pl unknown
- 2018-10-09 JP JP2020540866A patent/JP7237269B2/ja active Active
- 2018-10-09 CA CA3077506A patent/CA3077506A1/en active Pending
- 2018-10-09 ES ES18796753T patent/ES2911894T3/es active Active
- 2018-10-09 RU RU2020111694A patent/RU2020111694A/ru unknown
-
2022
- 2022-07-17 US US17/866,513 patent/US11897858B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220363655A1 (en) | 2022-11-17 |
| EP3694843B1 (en) | 2022-01-26 |
| CA3215809A1 (en) | 2019-04-18 |
| KR20200067152A (ko) | 2020-06-11 |
| JP7237269B2 (ja) | 2023-03-13 |
| EP3694843A1 (en) | 2020-08-19 |
| ES2911894T3 (es) | 2022-05-23 |
| RU2020111694A (ru) | 2021-11-12 |
| KR102505669B1 (ko) | 2023-03-03 |
| CA3077506A1 (en) | 2019-04-18 |
| JP2020536961A (ja) | 2020-12-17 |
| WO2019073388A1 (en) | 2019-04-18 |
| CN111194312A (zh) | 2020-05-22 |
| AU2018349284B2 (en) | 2023-11-16 |
| AU2018349284A1 (en) | 2020-04-30 |
| US11390597B2 (en) | 2022-07-19 |
| US20210380550A1 (en) | 2021-12-09 |
| US11897858B2 (en) | 2024-02-13 |
| PL3694843T3 (pl) | 2022-06-20 |
| RU2020111694A3 (es) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018073384A2 (pt) | polinucleotídeos moduladores | |
| ECSP19026178A (es) | Anticuerpos anti-pd-1 y sus usos | |
| CL2018000595A1 (es) | Anticuerpos anti-pd1 y métodos de uso | |
| ECSP18007905A (es) | Anticuerpos monoclonales contra bcma | |
| DOP2019000165A (es) | Anticuerpos anti-ox40 y sus usos | |
| CL2018000829A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| TWD175999S (zh) | 錶 | |
| CR20180605A (es) | Anticuerpos anti-cd40 y sus usos | |
| CL2018003087A1 (es) | Síntesis de indazoles. | |
| CL2017003240A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
| CL2018002092A1 (es) | Forma cristalina a de agonista de tlr7, su proceso de preparación y uso | |
| CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| CO2019012957A2 (es) | Inhibidores de quinasa y usos de los mismos | |
| CL2017000640A1 (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
| CL2017003124A1 (es) | Moduladores alostéricos positivos del receptor de m2 muscarínico | |
| BR112019003987A2 (pt) | formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc | |
| BR112019006030A2 (pt) | formas cristalinas e de sal de compostos agonistas de ppar | |
| ECSP20021132A (es) | Enantiómeros de tiazoles sustituidos compuestos antivirales | |
| UY36396A (es) | Síntesis de copanlisib y su sal diclorhidrato | |
| MX2020003730A (es) | Nueva sal y formas en estado solido de escitalopram. | |
| CL2021000855A1 (es) | Replicones basados en alfavirus para la administración de bioterapias. | |
| CR20150369A (es) | Método para preparar fideos instantáneos, composición de harina para fideos instantáneos y uso de la misma | |
| ECSP21021189A (es) | Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso |